Related Experiment Videos
Goals of statin therapy: three viewpoints
Gilbert R Thompson1, Christopher J Packard, Neil J Stone
1Metabolic Medicine, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN, United Kingdom. g.thompson@ic.ac.uk
Insights
The link between lower serum cholesterol and increased longevity is established. However, the optimal target for cholesterol reduction remains uncertain, pending results from ongoing major trials.
Area of Science:
- Cardiovascular Medicine
- Preventive Cardiology
- Lipid Metabolism
Background:
- The "lipid hypothesis," linking cholesterol levels to health outcomes, is widely accepted.
- Extensive research has confirmed that reducing serum cholesterol improves longevity.
- Current therapeutic strategies focus on patients with cholesterol levels above the population mean.
Purpose of the Study:
- To address the remaining uncertainty regarding the optimal extent of cholesterol reduction for therapeutic goals.
- To explore different perspectives on target cholesterol levels for intervention.
- To inform clinical practice as definitive data from ongoing trials is awaited.
Main Methods:
- Review of existing clinical trial data on cholesterol-lowering interventions.
- Expert opinion and argumentation from leading investigators in the field.
- Discussion of the implications of current evidence for therapeutic target setting.
Main Results:
- While the benefit of cholesterol reduction is proven, the precise target level is debated.
- Different expert viewpoints exist on the ideal therapeutic goal for cholesterol management.
- The need for further data from large-scale, ongoing studies is highlighted.
Conclusions:
- The established benefit of lowering serum cholesterol for longevity is undisputed.
- The optimal therapeutic target for cholesterol reduction requires further investigation.
- Ongoing large-scale trials are crucial for defining definitive treatment goals.
Abstract:
The "lipid hypothesis" is now universally recognized as a law. Few issues in medicine are as completely resolved as the question of whether reducing serum cholesterol increases longevity. However, there are a few questions that remain, and the most important uncertainty is to what extent cholesterol should be reduced. The medical community, in partnership with government and industry, has contributed many excellent trials demonstrating the effects in patients with elevated cholesterol (above the mean). Where should our goal of therapy be? Until data is available from several large, ongoing trials, we do not have a final answer. We asked three investigators, Drs. Gilbert Thompson, Christopher Packard, and Neil Stone, who have all been integrally involved in the accumulation of our present database, to argue three different possible answers.